A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

What Was Tested

This registered phase 2 trial tested MariTide (Maridebart Cafraglutide).

It had two arms (groups): Maridebart Cafraglutide (experimental) and Placebo (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

The registry lists 409 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥ 18 years at screening (or ≥ legal age within the country if it is older than 18 years). Type 2 diabetes for ≥6 months according to the World Health Organization classification. Body mass index of 23 to 50 kilograms per square meter.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got MariTide (Maridebart Cafraglutide) and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on MariTide (Maridebart Cafraglutide), so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2024-11-07 with completion listed for 2025-10-06.

It ran at 96 sites in United States (28), Hungary (10), Japan (8), Poland (7), Greece (6) and Italy (6).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (time frame: Baseline to Week 24).

It also tracked 21 secondary outcomes, for example Percent Change From Baseline to Week 24 in Body Weight, Change From Baseline to Week 24 in Fasting Glucose, Percent Change From Baseline to Week 24 in Total Cholesterol, Percent Change From Baseline to Week 24 in Low-density Lipoprotein Cholesterol (LDL-C), Percent Change From Baseline to Week 24 in High-density Lipoprotein Cholesterol (HDL-C) and Percent Change From Baseline to Week 24 in Non-high Density Lipoprotein Cholesterol (non-HDL-C).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of MariTide (Maridebart Cafraglutide) in 409 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the MariTide (Maridebart Cafraglutide) compound page, all human trials.